Dictionary

allow_url_fopen is ENABLED Dictionary Search

haemophilia b

Synonyms

Noun

1. hemophilia B

2. haemophilia B, Christmas disease, hemophilia, haemophilia, bleeder's disease

Usage
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Explainer 2025 Why Is Hemophilia B Called Christmas Disease - Global Biotechnology Company
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B | New England Journal of Medicine - The New England Journal of Medicine
Gene therapy can help reduce joint bleeds in hemophilia B: New data - Hemophilia News Today
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
First German haemophilia B patient receives gene therapy HEMGENIX - PharmaTimes
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - European Medical Journal
How durable is gene therapy for haemophilia B? - Nature
Clinical trial: Hemophilia B, (NCT06379789) - CRISPR Medicine - CRISPR Medicine News
NICE Recommends First Subcutaneous Option for Haemophilia B - Medscape
Number of people with bleeding disorders worldwide in 2024, by condition - Statista
Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study - The New England Journal of Medicine
Marstacimab Superior to On-Demand Prophylaxis for Hemophilia A, B, With Inhibitors - Docwire News
Hemophilia B gene therapy benefits last more than a decade: Study - Hemophilia News Today
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B | New England Journal of Medicine - The New England Journal of Medicine
Patients With Hemophilia Face Significant Burden Despite Treatment Type or Disease Severity - Docwire News
AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
First NHS patient treated with CSL Behring’s haemophilia B gene therapy Hemgenix - PMLiVE
Patient in Germany gets hemophilia B gene therapy Hemgenix - Hemophilia News Today
Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care - Frontiers
Haemophilia gene therapy patients thriving over a decade after treatment - University College London
Exploring Eptacog Beta Dosing in Patients With Hemophilia A or B - Docwire News
First-in-human trial of hemophilia B treatment BE-101 starts dosing - Hemophilia News Today
Transformative approaches in hemophilia management: from traditional therapies to prenatal stem cell treatment - Frontiers
HOPE-B: 5-Year Etranacogene Dezaparvovec Maintains Durable Efficacy and Safety in Hemophilia B, With Steven Pipe, MD - HCPLive
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Eloctate, Alprolix control bleeds in hemophilia patients’ major surgeries - Hemophilia News Today
Hemophilia B Gene Therapy Shows Promise as Long-Term Treatment - Docwire News
NICE recommends weekly injection for severe haemophilia B - The Pharmaceutical Journal
One dose of gene therapy gives years of relief from blood disorder - Nature
China Explores Weight-Based Pricing for First Domestic Hemophilia B Gene Therapy - NAVLIN DAILY
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors - PR Newswire
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors - Business Wire
(marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need - Business Wire
Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients - PMLiVE
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B - Yahoo Finance
UK Approves Marstacimab for Severe Haemophilia A or B - Medscape
Hull teenager first to be treated with new haemophilia drug - BBC
European Medicines Agency Issues Positive Opinion for Concizumab Label Update in Hemophilia - Docwire News
Spotlight on the ISTH Hemophilia Treatment Guidelines and Alternate Recommendations - Hematology Advisor
Hemophilia gene therapy: A new era of treatment and the obstacles ahead - Drug Discovery News
Belief, Takeda’s home-grown haemophilia B gene therapy gains nod in China - FirstWord Pharma
NMPA approves BBM and Takeda China’s haemophilia B therapy - Pharmaceutical Technology
Systemic lupus erythematosus caused acquired hemophilia B without evidence of factor IX inhibitors - Wiley Online Library
Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use - PMLiVE
Six biotech companies leading the charge in hemophilia treatment - Labiotech.eu
Extended hemophilia half-life products aid care, but raise costs - Hemophilia News Today
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations - Managed Healthcare Executive
EVOLVING THE TREATMENT LANDSCAPE WITH THE FIRST THERAPY APPROVED FOR PEOPLE WITH HEMOPHILIA A AND B WITH OR WITHOUT INHIBITORS - AJMC
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A - Citeline News & Insights
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors - BioSpace
NHS treats first haemophilia B patient with gene therapy - Progress Educational Trust
Pfizer reports positive results from Phase III BASIS trial for haemophilia - Clinical Trials Arena
FDA Expands Approval of Concizumab-mtci to Include Hemophilia A, B Without Inhibitor Use - Pharmacy Times
Novo Nordisk’s Haemophilia B Study: Key Update on Nonacog Beta Pegol - TipRanks
Expanding Alhemo to hemophilia without inhibitors recommended - Hemophilia News Today
FDA expands approvals for Novartis lipid drug, Novo haemophilia prophylatic - FirstWord Pharma
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report - Wiley
Pfizer's weekly haemophilia drug backed for NHS use - pharmaphorum
Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors - GOV.UK
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Switching to Extended Half-Life Therapies Improves Hemophilia Care, but Raises Short-Term Costs - Managed Healthcare Executive
How pioneering gene therapy changed the life of the first man in Wales to receive it - Nation.Cymru
Invited Medical Presentation Abstracts - 2025 - Haemophilia - Wiley Online Library
CSL’s haemophilia therapy shows durable five-year benefits in landmark trial results - BiotechDispatch
HHS pharmacy sets national benchmark: First-ever delivery of groundbreaking $4.5M Hemophilia B treatment - Hospital News
Gene therapy frees hemophilia patient from constant worry, needles - Harvard Gazette
Gene therapy BBM-H901 approved for hemophilia B in China - Hemophilia News Today
Hemophilia B Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Novo Nordisk, Sanofi, Pfizer, Belief BioMed, Centessa Pharmaceuticals - Barchart.com
Pfizer’s Hympavzi granted MHRA approval to treat haemophilia A and B - PMLiVE
Get easily bruised? It may be due to haemophilia B - healthshots.com
First Hemophilia B Patient Receives Hemgenix in Austria - NAVLIN DAILY
First gene therapy to treat haemophilia B - European Medicines Agency
First subcutaneous treatment for severe Haemophilia B recommended - National Health Executive
First NHS patient given world's most expensive drug that costs £2.6 million per dose - LADbible
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years - Mynewsdesk
Novo Nordisk’s Alhemo Recommended for Expanded Use in Europe for Haemophilia A and B - Insider Monkey
With hemophilia B, a lifetime of worry eased with one infusion - Penn Today
First hemophilia B patients in Denmark treated with Hemgenix –... - Hemophilia News Today
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - The New England Journal of Medicine
Man battling disease since he was a baby incredibly no longer needs weekly treatment - Wales Online
Researchers welcome $3.5-million haemophilia gene therapy — but questions remain - Nature
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B - The New England Journal of Medicine
Sanofi’s Qfitlia granted FDA approval to treat haemophilia A or B - PMLiVE
Transformational therapy cures haemophilia B - BBC
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients - Pharmaceutical Technology
Real Stories from People Living with Hemophilia - Centers for Disease Control and Prevention | CDC (.gov)
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond - The Lancet
Groundbreaking treatment for haemophilia administered in Wales for first time - Nation.Cymru
Haemophilia - The Lancet
Germany will reimburse haemophilia gene therapy Hemgenix - pharmaphorum
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
CSL Behring treats two patients with gene therapy for haemophilia B - Clinical Trials Arena
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors | New England Journal of Medicine - The New England Journal of Medicine
Foreign Language Equivalents
Foreign Language Equivalents of 'haemophilia b'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
haemopilia b,   haemophlia b,   haemophiliaa b,   haemophikia b,   haemophiliia b,   haemopphilia b,   haeemophilia b,   haemophilia b,   haemophili b,   haemophilai b,   haemophilia v,   haemophila b,   haemophulia b,   haemophillia b,   haeophilia b,   haemophilua b,   haemoohilia b,   haemophliia b,   haemophi;ia b,   gaemophilia b,   haemophhilia b,   aemophilia b,   hemophilia b,   haemphilia b,   haempphilia b,   hamophilia b,   haemophilia n,   hhaemophilia b,   haaemophilia b,   haemopgilia b,   harmophilia b,   haempohilia b,   haemophiloa b,   haemiphilia b,   heamophilia b,   hawmophilia b,   haemopihlia b,   haemoophilia b,   haemophilia bb,   haenophilia b,   jaemophilia b,   haemophiliab ,   hae,ophilia b,   haemopjilia b,   haemopholia b,   haemo[hilia b,   haemophili ab,   ahemophilia b,   haemophilis b,   haeomphilia b,   hsemophilia b,   hameophilia b,   haemophiia b,   haemophiliab,   haemophilia ,   haemophiila b,   haemmophilia b,   haemohilia b,   haemohpilia b,   haemophiilia b
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z